ombitasvir

Known as: Carbamic Acid, N,N'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)bis(4,1-phenyleneiminocarbonyl-(2S)-2,1-pyrrolidinediyl((1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl)))bis-, C,C'-Dimethyl Ester, L-Prolinamide,2,2'-(((2S,5S)-1-(4-(1,1-dimethylethyl)phenyl)-2,5-pyrrolidinediyl)di-4,1-phenylene)bis(N-(methoxycarbonyl)-L-valy, dimethyl ([(2S,5S)-1-(4-tert-butylphenyl)pyrrolidine-2,5-diyl]bis{(4,1-phenylene)carbamoyl(2S)pyrrolidine-2,1-diyl[(2S)-3-methyl-1-oxobutane-1,2-diyl]})biscarbamate 
An orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against… (More)

Topic mentions per year

Topic mentions per year

2014-2018
05010020142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
IMPORTANCE Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver… (More)
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Hepatitis C virus (HCV) genotype 4 accounts for about 13% of global HCV infections. Because interferon-containing… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2015
2015
Ombitasvir (ABT-267) is a hepatitis C virus (HCV) NS5A inhibitor with picomolar potency, pan-genotypic activity, and 50… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?
2015
2015
BACKGROUND & AIMS Paritaprevir (administered with ritonavir, PTV/r), ombitasvir (OBV), and dasabuvir (DSV) are direct-acting… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
UNLABELLED GIFT-I is a phase 3 trial evaluating the efficacy and safety of a 12-week regimen of coformulated ombitasvir (OBV… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND The interferon-free combination of the protease inhibitor ABT-450 with ritonavir (ABT-450/r) and the NS5A inhibitor… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND The interferon-free regimen of ABT-450 with ritonavir (ABT-450/r), ombitasvir, and dasabuvir with or without ribavirin… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Hepatitis C virus (HCV) infection is the leading indication for liver transplantation worldwide, and interferon… (More)
  • table 1
  • table 2
  • table 4
  • table 3
Is this relevant?